2. Academic Validation
  3. Reviving the guardian of the genome: Small molecule activators of p53

Reviving the guardian of the genome: Small molecule activators of p53

  • Pharmacol Ther. 2017 Oct;178:92-108. doi: 10.1016/j.pharmthera.2017.03.013.
Daniel Nguyen 1,  Wenjuan Liao 1,  Shelya X Zeng 1,  Hua Lu 2
Affiliations

Affiliations

  • 1 Department of Biochemistry and Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave, LA 70012, United States.
  • 2 Department of Biochemistry and Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave, LA 70012, United States. Electronic address: hlu2@tulane.edu.
PMID: 28351719 DOI: 10.1016/j.pharmthera.2017.03.013
Abstract

The tumor suppressor p53 is one of the most important proteins for protection of genomic stability and Cancer prevention. Cancers often inactivate it by either mutating its gene or disabling its function. Thus, activating p53 becomes an attractive approach for the development of molecule-based anti-cancer therapy. The past decade and half have witnessed tremendous progress in this area. This essay offers readers with a grand review on this progress with updated information about small molecule activators of p53 either still at bench work or in clinical trials.

Keywords

Drug discovery; Inauhzin; MDM2; MDMX; Small molecules; p53.

Figures
Products